Outcomes in randomized controlled trials in psoriasis: What has changed over the last 20 years?

Journal of Dermatological Treatment

Volumn 18, Issue 5, 2007, Pages 261-267

  Morsy, Hanan ^a   Kamp, Soren ^a   Jemec, Gregor B E ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Assessment tools; Psoriasis

Indexed keywords

CLINICAL ASSESSMENT TOOL; CLINICAL EVALUATION; DATA ANALYSIS; DISEASE SEVERITY; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSORIASIS; QUALITY OF LIFE; REVIEW; SCORING SYSTEM; TREATMENT OUTCOME;

DERMATOLOGIC AGENTS; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PSORIASIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; SKIN;

EID: 35148832654     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630701487635     Document Type: Review

References (37)

1. Jobling RG. Psoriasis - A preliminary questionnaire study of sufferers' subjective experience. Clin Exp Dermatol. 1976;1:233-6.
2. Jowett S, Ryan T. Skin disease and handicap: An analysis of the impact of skin conditions. Soc Sci Med. 1985;20:425-9.
3. Ashcroft DM, Wan Po AL, Williams HC, Griffiths CE. Clinical measures of disease severity and outcome in psoriasis: A critical appraisal of their quality. Br J Dermatol. 1999;141:185-91.
4. Marks R, Barton SP, Shuttleworth D, Finlay AY. Assessment of disease progress in psoriasis. Arch Dermatol. 1989;125:235-40.
5. Carroll CL, Feldman SR, Camacho FT, Balkrishman R. Better medication adherence results in greater improvement in severity of psoriasis. Br J Dermatol. 2004;151:895-7.
6. Vahlquist A, Torma H, Carlsson B. Inefficacy of topical thyroid hormone analogue TriAc in plaque psoriasis: Results of a double-blind placebo-controlled trial. Br J Dermatol. 2004;151:489-91.
7. Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol. 2004;51:563-9.
8. Allan SJ, Kavanagh GM, Herd RM, Sarin JA. The effect of inositol supplements on the psoriasis of patients taking lithium: A randomized, placebo-controlled trial. Br J Dermatol. 2004;150:966-9.
9. Kragballe K, Noerrelund KL, Lui H, Ortonne JP, Wozel J, Uurasmaa T, et al. Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris. Br J Dermatol. 2004;150:1167-73.
10. Feldman SR, Menter A, Koo JY. Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis. Br J Dermatol. 2004;150:317-26.
11. Durakovic C, Ray S, Holick MF. Topical paricalcitol (19-nor-1 alpha,25-dihydroxyvitamin D2) is a novel, safe and effective treatment for plaque psoriasis: A pilot study. Br J Dermatol. 2004;151:190-5.
12. Grundmann-Kollmann M, Ludwig R, Zollner TM, Ochsendorf F, Thaci D, Boehncke W, et al. Narrow-band UVB and cream psoralen-UVA combination therapy for plaque-type psoriasis. J Am Acad Dermatol. 2004;50:734-9.
13. Legat FJ, Hofer A, Quehenberger F, Kahofer P, Kerl H, Wolf P. Reduction of treatment frequency and UVA dose does not substantially compromise the antipsoriatic effect of oral psoralen-UVA. J Am Acad Dermatol. 2004;51:746-54.
14. Gribetz C, Ling M, Lebwohl M, Pariser D, Draelos Z, Gottlieb AB, et al. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: A double-blind, randomized study. J Am Acad Dermatol. 2004;51:731-8.
15. Lebwohl M, Freeman AK, Chapman MS, Feldman SR, Hartle JE, Henning A. Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol. 2004;51:723-30.
16. Opmeer BC, Heydendael VM, De Borgie CA, Spuls PI, Bossuyt PM, Bos JD, et al. Costs of treatment in patients with moderate to severe plaque psoriasis: economic analysis in a randomized controlled comparison of methotrexate and cyclosporine. Arch Dermatol. 2004;140:685-90.
17. Gottlieb AB, Evans R, Li S, Dooley LT, Guzzo CA, Baker D, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2004;51:534-42.
18. Van de Kerkhof PC. The impact of a two-compound product containing calcipotriol and betamethasone dipropionate (Daivobet/Dovobet) on the quality of life in patients with psoriasis vulgaris: A randomized controlled trial. Br J Dermatol. 2004;151:663-8.
19. Radakovic-Fijan S, Blecha-Thalhammer U, Schleyer V, Sziemies RM, Zwingers T, Honigsmann H, et al. Topical aminolaevulinic acid-based photodynamic therapy as a treatment option for psoriasis? Results of a randomized, observer-blinded study. Br J Dermatol. 2005;152:279-83.
20. Asawanonda P, Chingchai A, Torranin P. Targeted UV-B phototherapy for plaque-type psoriasis. Arch Dermatol. 2005;141:1542-6.
21. Carroll CL, Clarke J, Camacho F, Balkrishman R, Feldman SR. Topical tacrolimus ointment combined with 6% salicylic acid gel for plaque psoriasis treatment. Arch Dermatol. 2005;141:43-6.
22. Gottlieb AB, Griffiths CE, Ho VC, Lahfa M, Mrowietz U, Murrell DF, et al. Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: A double-blind, multicentre, randomized, dose-finding trial. Br J Dermatol. 2005;152:1219-27.
23. Ormerod AD, Shah SA, Copeland P, Omar G, Winfield A. Treatment of psoriasis with topical sirolimus: Preclinical development and a randomized, double-blind trial. Br J Dermatol. 2005;152:758-64.
24. Leonardi CL, Papp KA, Gordon KB, Menler A, Feldman SR, Caro I, et al. Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trial. J Am Acad Dermatol. 2005;52:425-33.
25. Dawe RS, Yule S, Cameron H, Moseley H, Ibbotson SH, Ferguson J. A randomized controlled comparison of the efficacy of Dead Sea salt balneophototherapy vs narrow-band ultraviolet B monotherapy for chronic plaque psoriasis. Br J Dermatol. 2005;153:613-19.
26. Krueger GG, Langley RG, Finlay AY, Griffiths CE, Woolley JM, Lalla D, et al. Patient-reported outcomes of psoriasis improvement with etanercept therapy: Results of a randomized phase III trial. Br J Dermatol. 2005;153:1192-9.
27. Menter A, Gordon K, Carey W, Hamilton T, Glazer S, Caro I, et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol. 2005;141:31-8.
28. Feldman SR, Gordon KB, Bala M, Evans R, Li S, Dooley LT, et al. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: A double-blind placebo-controlled trial. Br J Dermatol. 2005;152:954-60.
29. Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CE, Nakanishi AM, et al. A global phase III randomized controlled trial of etanercept in psoriasis: Safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005;152:1304-12.
30. Bissonnette R, Papp K, Poulin Y, Lauzon G, Aspeslets L, Huizinga R, et al. A randomized, multicenter, double-blind, placebo-controlled phase 2 trial of ISA247 in patients with chronic plaque psoriasis. J Am Acad Dermatol. 2006;54:472-8.
31. Naldi L, Svensson A, Diepgen T, Elsner P, Grob J, Goenraads P, et al. Randomized clinical trials for psoriasis 1977-2000: the EDEN survey. J Invest Dermatol. 2003;120:738-41.
32. Holm EA, Jemec GBE. General Guidelines for Assessment of skin disease. In: Serup J, Jemec GBE, Grove G, editors. Handbook of non-invasive methods and the skin. 2nd ed. Boca Ratron: CRC; 2006;931-42.
33. Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis. 2005;64 suppl 2:ii65-8.
34. Feldman SR. The design of clinical trials in psoriasis: Lessons for clinical practice. J Am Acad Dermatol. 2003;49:S62-5.
35. Kirby B, Fortune DG, Bhushan M, Chalmers RJ, Griffiths CE. The Salford Psoriasis Index: An holistic measure of psoriasis severity. Br J Dermatol. 2000;142:728-32.
36. Jemec GB, Wulf HC. The applicability of clinical scoring systems: SCORAD and PASI in psoriasis and atopic dermatitis. Acta Derm Venereol. 1997;77:392-3.
37. Holm EA, Wulf HC, Stegmann H, Jemec GB. Life quality assessment among patients with atopic eczema. Br J Dermatol. 2006;154:719-25.